ALK and neuroblastoma: Mutations in the RAS pathway occur frequently in neuroblastoma, not only in the RAS gene itself, but also through mutations in regulatory proteins and downstream signaling components (e.g., NF1 and PTPN11) or by triggering constitutive activation of the receptor kinases of the pathway (e.g., ALK) (68).